LON:RENE - ReNeuron Group Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 75 -1.00 (-1.32 %) (As of 03/20/2019 03:05 AM ET)Previous CloseGBX 76Today's RangeGBX 75 - GBX 7552-Week RangeGBX 1.37 - GBX 142.50Volume120,105 shsAverage Volume28,700 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom. Receive RENE News and Ratings via Email Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:RENE Previous Symbol CUSIPN/A CIKN/A Webwww.reneuron.com Phone+44-20-38198400Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees62 Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable ReNeuron Group (LON:RENE) Frequently Asked Questions What is ReNeuron Group's stock symbol? ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE." How were ReNeuron Group's earnings last quarter? ReNeuron Group Plc (LON:RENE) announced its quarterly earnings results on Friday, December, 14th. The company reported ($16.80) earnings per share (EPS) for the quarter. View ReNeuron Group's Earnings History. Has ReNeuron Group been receiving favorable news coverage? News headlines about RENE stock have trended negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ReNeuron Group earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of ReNeuron Group's key competitors? Some companies that are related to ReNeuron Group include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM), China Longyi Group Int'l (CGYG), Creative Medical Technology (CELZ) and Cyclacel Pharmaceuticals Inc 6% Conv. Pref. Shrs (CYCCP). What other stocks do shareholders of ReNeuron Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), AXA (CS), Lloyds Banking Group (LLOY), Regenxbio (RGNX), Connect Group (CNCT), Sirius Minerals (SXX), ValiRx (VAL), Independent Oil & Gas (IOG) and Spark Therapeutics (ONCE). Who are ReNeuron Group's key executives? ReNeuron Group's management team includes the folowing people: Mr. Olav Hellebø, CEO & Director (Age 54)Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)Dr. Randolph Corteling, Head of ResearchMr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs How do I buy shares of ReNeuron Group? Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is ReNeuron Group's stock price today? One share of RENE stock can currently be purchased for approximately GBX 75. What is ReNeuron Group's official website? The official website for ReNeuron Group is http://www.reneuron.com/. How can I contact ReNeuron Group? ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400. MarketBeat Community Rating for ReNeuron Group (LON RENE)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 159 (Vote Outperform)Underperform Votes: 97 (Vote Underperform)Total Votes: 256MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What is a stock split?